Entries by Nascent

Nascent Biotech Inc. Raises $1.2 Million in Initial Funding

San Diego, CA, Nascent Biotech Inc (NBIO: OTC) announced today that it has recently closed a non-brokered private placement round for aggregate gross proceeds of $1.2Million. Management raised funds and the use of Proceeds will be for developing antibodies used to treat cancer; including manufacturing, preparation for human clinical trials, general working capital and administration. […]

2015 Human Antibodies & Hybridomas Conference

Nascent Biotech will be a key sponsor of the 2015 edition of the Human Antibodies & Hybridomas Conference, held October 28-30, 2015, at the University of Lausanne/CHUV, in Lausanne, Switzerland. Nascent Biotech CEO Mark Glassy will serve as the program chairman of the Scientific Advisory Committee. The conference scope will include: Infectious Diseases · Autoimmunity […]

Nascent team members author “Oligoclonal and Polyclonal Antibody Preparations” paper

Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta authored a new paper published in the Handbook of Therapeutic Antibodies, Second Edition, edited by Stefan Dübel and Janice M. Reichert (Wiley-VCH). Gupta, R. and Glassy, M. Oligoclonal and Polyclonal Antibody Preparations; in: Handbook of Therapeutic Antibodies; […]

Nascent Team Members Contribute to “Human Monoclonal Antibodies” (Humana Press)

Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta have contributed a chapter to Humana Press’ new book “Human Monoclonal Antibodies: Methods and Protocols,” edited by Michael Steinitz. Glassy, M and Gupta, R. Technical and Ethical Limitations in Making Human Monoclonal Antibodies (an overview).  In: Human […]

Jin-En International Group Holding Co. Acquires Nascent Biologics and Changes Name to Nascent Biotech Inc.

Ft Lauderdale FL July 29, 2014 – Jin-En International Group Holding Co. (“Jin-en” or “the Company”) (PINK.BB: JINZ), is pleased to announce the acquisition 100% of the outstanding shares of Nascent Biologics, a Nevada corporation (“NBI”). As part of the acquisition, the Company has agreed to change its name to Nascent Biotech Inc. and plans […]

American Cancer Society 2014 Cancer Facts and Figures

Please click to download the 2014 Cancer Facts and Figures PDF released by the American Cancer Society. In addition, please review this document, entitled “Cancer Statistics, 2011; The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths” in PDF format.

Use of the GPEx® System to Increase Production of Pritumumab in a CHO Cell Line

The Journal of Bioprocess Technology has published a paper co-authored by Nascent Biologics Inc. co-founder and chief executive officer Dr. Mark C. Glassy, PhD, entitled “Use of the GPEx® System to Increase Production of Pritumumab in a CHO Cell Line.” This study highlights NBI’s relationship with Catalent, detailed here. From the paper’s abstract: Expression of […]

Catalent to Contribute Expertise on Pipeline Progression at European Antibody Congress 2012

Somerset, NJ, November 20 2012 – Dr. Greg Bleck, R&D Platform Director-Biologics, Catalent Pharma Solutions, will participate in a panel discussion titled “How collaboration can lead to faster pipeline progression”, on Wednesday 28th November at the European Antibody Congress 2012 (27 – 28 November 2012, Starling Geneva Hotel & Conference Center, Geneva, Switzerland). Part of […]

Genengnews.com: Catalent to Use Mammalian Cell Platform to Generate Nascent’s Anticancer Antibody

The following article appeared at Genetic Engineering & Biotechnology News on April 17, 2012: Catalent to Use Mammalian Cell Platform to Generate Nascent’s Anticancer Antibody Nascent Biologics signed an antibody development deal with Catalent Pharma Solutions through which the latter will use its GPEx® technology to engineer a cell line expressing Nascent’s pritumumab antibody for […]

Nascent and Catalent Sign Cancer Antibody Development Deal

SOMERSET, NJ, and SAN DIEGO, CA – April 16, 2012 — Nascent Biologics, Inc. and Catalent Pharma Solutions today announced the signing of a product development agreement. Under the terms of the agreement, Catalent will engineer a cell line expressing Nascent’s proprietary “Pritumumab” antibody using Catalent’s GPExÒ technology, and will subsequently produce purified monoclonal antibody […]